A drug that recently received accelerated approval from FDA to treat a form of non-small cell lung cancer caused by a unique genetic mutation also appears to be effective against advanced pancreatic cancer caused by the same uncommon mutation.
An analysis led by a researcher at UT Southwestern Medical Center, which looked at costs for patients with Hepatocellular carcinoma in the first year after diagnosis, found that median Medicare payments exceeded $65,000 and out-of-pocket costs were more than $10,000—significantly more than costs for patients with cirrhosis alone.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Yale Cancer Center scientists have developed a technology that enables massively parallel DNA substitutions (known as “knock-ins”) into human cells by taking advantage of messenger RNA, a platform now well-known from its use as the COVID vaccine vehicle.
In a study published in Cell Reports Medicine, a team of scientists at Baylor College of Medicine focused on the molecular pathways metastatic cancer cells use and identified four cancer subtypes according to the main genes expressed. The findings unveiled potential vulnerabilities of each subtype that have relevant implications for therapy.
Researchers at Baylor College of Medicine, the University of Michigan, and collaborating institutions working with animal models of graft-versus-host disease reported in Immunity that alterations in the gut microbiome are connected to an increase in the oxygen levels in the intestine that follows immune-mediated intestinal damage. Pharmacologically reducing intestinal oxygen levels alleviated the microbial imbalance and reduced the severity of the intestinal disease.
To mark World Cancer Day, researchers from the International Agency for Research on Cancer in collaboration with the Lalla Salma Foundation for Cancer Prevention and Treatment (Morocco) published a report that provides solutions to overcoming some of the common system-level barriers to implementation of cervical cancer screening, which are faced in many countries in sub-Saharan Africa.
Investigators from Rutgers Cancer Institute of New Jersey found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis.
A study, published in The Lancet Oncology, reports large international differences in survival among patients diagnosed with 15 common cancer types in Asia, Africa, and Latin America and the Caribbean.
TRANSCEND CLL 004, a phase I/II, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, met its primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor.
